Michael W. Lu

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.7K citations · Full text

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Ian E. Krop, Patricia LoRusso, Kathy D. Miller et al. · Journal of Clinical Oncology · 2012 · 361 citations · Full text

Evaluating eligibility criteria of oncology trials using real-world data and AI

Ruishan Liu, Shemra Rizzo, Samuel Whipple et al. · Nature · 2021 · 282 citations · Full text

Oncology Trials, Medicine, Real-world Data +9

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Solange Peters, Rolf A. Stahel, Lukas Bubendorf et al. · Clinical Cancer Research · 2018 · 224 citations · Full text

A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

Muralidhar Beeram, Ian E. Krop, Howard A. Burris et al. · Cancer · 2012 · 102 citations · Full text